The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-Down to Earth Biometric-based unique identity or Aadhaar is leading to huge problems for people working for the rural employment guarantee scheme and for others receiving welfare benefits. Not only have enrolments been done shoddily but the experience of the pilot projects shows that it is almost impossible to authenticate the work-hardened fingerprints of the poor, find Latha Jishnu and Jyotika Sood. Besides, there is the overwhelming issue of deficient online...

-Reuters NEW DELHI (TrustLaw) - About 60 percent of Indian women have no access to family planning services, giving them little control over their bodies and slowing efforts to boost human development indicators, said the head of the U.N. Population Fund (UNFPA). Human development indicators cover health, education and living standards. India, Asia's third-largest economy, is set to overtake China as the world's most populous nation by 2030. But, despite its impressive economic...

Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines, India’s central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunisation programme in seven of its provinces. Pentavalent vaccine doses, a cocktail of five antigens in a single shot, confers immunity against five paediatric diseases - diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib), with the last one considered particularly...

India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...